Key Takeaways
- Technical analysts have flagged a potential end to a recent price correction in Oscar Health ($OSCR), suggesting a resumption of its upward trend if key support levels are established.
- The technical narrative is now supported by a significant fundamental shift: Oscar achieved its first-ever profitable quarter in Q1 2024, reporting a net income of $177.4 million.
- This inflection from cash-burning growth to demonstrated profitability reframes the investment case, although its valuation remains rich compared to legacy health insurance incumbents.
- Key metrics to watch are the Medical Loss Ratio (MLR), which has shown marked improvement, and the company’s ability to sustain profitability amid competitive and regulatory pressures.
The recent price action in Oscar Health, Inc. (NYSE: OSCR) has captured the attention of technical traders, with some, such as the analyst StockTrader_Max, suggesting a classic corrective pattern may have concluded, paving the way for further gains. While chart patterns and Fibonacci levels provide a framework for short-term positioning, their predictive power is magnified when they align with a fundamental shift in the underlying business. For Oscar Health, such a shift appears to be underway, with the company’s recent achievement of profitability providing a substantive tailwind to the bullish technical narrative.
From Technical Theory to Fundamental Reality
The technical argument centres on a completed ‘ABC’ correction, a three-wave pattern that interrupts a prevailing trend. Proponents of this view are watching for the stock to establish firm support at a key Fibonacci retracement level, often the 0.382 or 0.50 mark of the prior upward move. A successful defence of such a level is frequently interpreted as confirmation that the primary trend is ready to resume. While a useful tool for traders, this technical perspective on Oscar Health gains considerable weight when viewed alongside the company’s operational turnaround.
The abstract world of chart patterns has met the concrete reality of the income statement. In the first quarter of 2024, Oscar Health reported its first-ever period of GAAP profitability, a milestone that fundamentally alters its investment thesis. The company posted a net income of $177.4 million on revenues of $2.1 billion. Crucially, this was not merely an accounting adjustment but was driven by tangible operational improvements, most notably a sharp decline in its Medical Loss Ratio (MLR) to 75.3%. A lower MLR indicates that a smaller portion of premium revenues is being spent on medical claims, pointing towards greater efficiency and underwriting discipline.
A New Valuation Paradigm
With profitability now demonstrated, the conversation around Oscar Health’s valuation must evolve. Previously assessed through the lens of a high-growth, cash-burning technology firm, it now invites comparison with established, profitable health insurance incumbents. The disparity, however, remains stark. While the company has proven it can generate a profit, its valuation continues to price in substantial future growth far exceeding that of its legacy peers.
A comparative look at key metrics illustrates the premium at which Oscar trades. This is the central tension for investors: balancing the demonstrated operational leverage of its technology-first model against a valuation that leaves little room for error.
| Metric | Oscar Health ($OSCR) | UnitedHealth Group ($UNH) | Cigna Group ($CI) |
|---|---|---|---|
| Market Capitalisation | ~$7.1 billion | ~$450 billion | ~$98 billion |
| Price / Sales (TTM) | ~1.0x | ~1.2x | ~0.5x |
| Medical Loss Ratio (Q1 2024) | 75.3% | 84.3% (UnitedHealthcare) | 82.2% |
Note: Figures are approximate and based on data as of late June 2024. Market capitalisation and P/S ratios are subject to market fluctuations.
The cautious stance from some quarters of the market, such as Barclays’ initial underweight rating, reflects this valuation concern. The bull case rests on Oscar’s ability to sustain its improved MLR and scale its model, thereby growing into its valuation. The bear case worries that the first profitable quarter may be an outlier and that competitive pressures within the Affordable Care Act (ACA) marketplaces will erode margins over time.
Forward Guidance and a Testable Hypothesis
Following its strong Q1 performance, Oscar’s management raised its full-year guidance, projecting adjusted EBITDA between $225 million and $275 million. This provides a clear benchmark against which the company’s performance can be measured. For investors and traders, the path forward involves monitoring not only technical price levels but, more importantly, the sustainability of the firm’s profitability metrics in its upcoming quarterly reports.
This leads to a speculative but critical hypothesis: Oscar’s entire long-term value proposition is predicated on the idea that its technology platform creates a durable competitive advantage in managing medical costs. If the firm can consistently maintain an MLR materially below the industry average as it continues to scale its member base, it could justify its premium valuation and emerge as a genuine disruptor. Conversely, if its MLR reverts towards the industry mean, the current share price may prove difficult to sustain, suggesting the recent profitability was a temporary achievement rather than a permanent new state of being.
References
Oscar Health. (2024, May 7). Oscar Health Announces First Quarter 2024 Results, Marking First Profitable Quarter as a Public Company and Raises Full Year 2024 Guidance. Retrieved from Oscar Health Investor Relations.
MarketBeat. (2024). Barclays Initiates Coverage on Oscar Health (NYSE:OSCR). Retrieved from MarketBeat.
Investopedia. (2024). Fibonacci Retracement and Gann Levels: Are They the Same?. Retrieved from Investopedia.
@StockTrader_Max. (2025, July). [Post suggesting a completed ABC correction in $OSCR]. Retrieved from https://x.com/StockTrader_Max/status/1925977662138224787
